Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)

Stopped Incyte made a strategic business decision to stop enrollment to all ongoing oral PD-L1 (99280) studies. This decision was made based on an internal review and reprioritization of the existing pipeline.

Conditions

• Hepatocellular Carcinoma

Interventions

• DRUG: INCB099280

Sponsor

Abramson Cancer Center at Penn Medicine

Collaborators

• [object Object]